keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical BCG

keyword
https://www.readbyqxmd.com/read/28406993/topical-and-systemic-immunoreaction-triggered-by-intravesical-chemotherapy-in-an-n-butyl-n-4-hydroxybutyl-nitorosamine-induced-bladder-cancer-mouse-model
#1
Shunta Hori, Makito Miyake, Yoshihiro Tatsumi, Sayuri Onishi, Yosuke Morizawa, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto
Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progression and recurrence of non-muscle invasive bladder cancer (NMIBC). Although the immunoreaction elicited by BCG treatment is well documented, those induced by intravesical treatment with chemotherapeutic agents are much less known. We investigated the immunological profiles caused by mitomycin C, gemcitabine, adriamycin and docetaxel in the N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced orthotopic bladder cancer mouse model...
2017: PloS One
https://www.readbyqxmd.com/read/28406148/bladder-cancer
#2
REVIEW
Oner Sanli, Jakub Dobruch, Margaret A Knowles, Maximilian Burger, Mehrdad Alemozaffar, Matthew E Nielsen, Yair Lotan
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours...
April 13, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28402764/ensuring-access-to-injectable-generic-drugs-the-case-of-intravesical-bcg-for-bladder-cancer
#3
Benjamin J Davies, Thomas J Hwang, Aaron S Kesselheim
In November 2016, one of the two manufacturers of bacille Calmette–Guérin (BCG) informed health care providers that it planned to exit the market in mid-2017. Intravesical immunotherapy with BCG is the standard of treatment for preventing recurrence and disease progression in high-risk patients..
April 13, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28389159/validation-of-the-ezrin-ck20-and-ki-67-as-potential-predictive-markers-for-bcg-instillation-therapy-of-non-muscle-invasive-bladder-cancer
#4
Per-Uno Malmström, Tammer Hemdan, Ulrika Segersten
OBJECTIVE: The aim of our study was to try to validate 3 promising predictive biomarkers in a database based on prospective trials comparing bacillus Calmette-Guerin (BCG) with mitomycin-C and a combination of epirubicin and interferon, respectively. BACKGROUND: The most common form of bladder cancer is non-muscle-invasive tumors treated initially with transurethral resection. Unfortunately more than half recur and some also progress. Consequently, an attempt to prevent poor outcome is frequently made by intravesical instillations either by chemo- or immunotherapy...
April 4, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28359179/tackling-non-muscle-invasive-bladder-cancer-in-the-clinic
#5
Solomon L Woldu, Öner Şanli, Yair Lotan
Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC - which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG)...
May 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28344356/methylation-status-as-a-predictor-of-intravesical-bacillus-calmette-gu%C3%A3-rin-bcg-immunotherapy-response-of-high-grade-non-muscle-invasive-bladder-tumor
#6
Petr Husek, Jaroslav Pacovsky, Marcela Chmelarova, Miroslav Podhola, Milos Brodak
BACKGROUND AND AIMS: Genetic and epigenetic alterations play an important role in urothelial cancer pathogenesis. Deeper understanding of these processes could help us achieve better diagnosis and management of this life-threatening disease. The aim of this research was to evaluate the methylation status of selected tumor suppressor genes for predicting BCG response in patients with high grade non-muscle-invasive bladder tumor (NMIBC). MATERIALS AND METHODS: We retrospectively evaluated 82 patients with high grade non-muscle-invasive bladder tumor (stage Ta, T1, CIS) who had undergone BCG instillation therapy...
March 22, 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/28339163/next-generation-sequencing-of-urine-specimens-a-novel-platform-for-genomic-analysis-in-patients-with-non-muscle-invasive-urothelial-carcinoma-treated-with-bacille-calmette-gu%C3%A3-rin
#7
Sasinya N Scott, Irina Ostrovnaya, Caroline M Lin, Nancy Bouvier, Bernard H Bochner, Gopakumar Iyer, David Solit, Michael F Berger, Oscar Lin
BACKGROUND: Biopsies from patients with high-risk (HR) non-muscle-invasive urothelial carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. This study evaluated the use of next-generation sequencing (NGS) analysis of urine cytology material from patients with HR NMIUC in an attempt to identify genetic alterations that might correlate with clinical features and responses to bacille Calmette-Guérin (BCG) treatment...
March 24, 2017: Cancer
https://www.readbyqxmd.com/read/28286068/efficacy-of-bacillus-calmette-guerin-strains-for-the-treatment-of-non-muscle-invasive-bladder-cancer-a-systematic-review-and-network-meta-analysis
#8
REVIEW
Brock E Boehm, John E Cornell, Hanzhang Wang, Neelam Mukherjee, Jacob S Oppenheimer, Robert S Svatek
PURPOSE: To determine the efficacy of genetically distinct Bacillus Calmette-Guérin (BCG) strains in preventing disease recurrence for patients with non-muscle invasive bladder cancer (NMIBC). EXPERIMENTAL DESIGN: We conducted a systematic review and network meta-analysis of trials evaluating BCG strains against all possible comparators (different BCG strains, chemotherapy, and non-BCG biologic therapies) and intravesical chemotherapy as the common comparator. MEDLINE served as the primary data source, with search from inception to October 2016 for clinical trials involving patients with NMIBC receiving BCG...
March 9, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28278504/assessing-the-feasibility-of-replacing-standard-dose-bacillus-calmette-gu%C3%A3-rin-immunotherapy-with-other-intravesical-instillation-therapies-in-bladder-cancer-patients-a-network-meta-analysis
#9
Cheng Wu, Xunrong Zhou, Chunqing Miao, Jianzhong Zhang, Qingsheng Tang, Xiumei Chang, Haodong Ni
BACKGROUND: Bacillus Calmette-Guérin (BCG) immunotherapy plays a key role in patients with bladder cancer. The shortage of intravesical BCG has motivated researchers to seek alternatives with equivalent efficacy If other alternative intravesical agents have equivalent efficacy compared to BCG, then it may be feasible to replace standard BCG with alternative options. METHODS: We searched all relevant evidence in multiple sources and key data was extracted from included studies...
March 8, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28268259/intravesical-bacillus-calmette-gu%C3%A3-rin-with-interferon-alpha-versus-intravesical-bacillus-calmette-gu%C3%A3-rin-for-treating-non-muscle-invasive-bladder-cancer
#10
REVIEW
Andrew Rh Shepherd, Emily Shepherd, Nicholas R Brook
BACKGROUND: Despite local therapies, commonly transurethral resection (TUR) followed by adjuvant treatments, non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence and progression. Intravesical Bacillus Calmette-Guérin (BCG) has been shown to reduce recurrence and progression in people with NMIBC following TUR, however many people do not respond to treatment, have recurrence shortly after, or cannot tolerate standard-dose therapy. The potential for synergistic antitumour activity of interferon (IFN)-alpha (α) and BCG provides some rationale for combination therapy for people who do not tolerate or respond to standard-dose BCG therapy...
March 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28250302/henoch-sch%C3%A3-nlein-purpura-nephritis-associated-with-intravesical-bacillus-calmette-guerin-bcg-therapy
#11
Hiroyuki Tsukada, Hiroshi Miyakawa
Henoch Schönlein purpura (HSP), also known as IgA vasculitis (IgAV), is a systemic small-vessel vasculitis that predominantly affects adolescents and is rare in adults. In many cases, the onset of HSP has been causally linked to an infectious disease. We encountered a case of HSP with severe renal involvement diagnosed by renal biopsy following bacillus Calmette-Guerin (BCG) therapy for bladder cancer. This is of clinical relevance, as intravesical BCG administration is becoming an established therapy for superficial bladder cancer and is supposed to be safe...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28248951/bcg-unresponsive-non-muscle-invasive-bladder-cancer-recommendations-from-the-ibcg
#12
REVIEW
Ashish M Kamat, Marc Colombel, Debasish Sundi, Donald Lamm, Andreas Boehle, Maurizio Brausi, Roger Buckley, Raj Persad, Joan Palou, Mark Soloway, J Alfred Witjes
Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer...
February 21, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28224172/multi-parametric-mri-findings-of-granulomatous-prostatitis-developing-after-intravesical-bacillus-calmette-gu%C3%A3-rin-therapy
#13
Josh Gottlieb, Robert Princenthal, Martin I Cohen
PURPOSE: To evaluate the multi-parametric MRI (mpMRI) findings in patients with biopsy-proven granulomatous prostatitis and prior Bacillus Calmette-Guérin (BCG) exposure. MATERIALS AND METHODS: MRI was performed in six patients with pathologically proven granulomatous prostatitis and a prior history of bladder cancer treated with intravesical BCG therapy. Multi-parametric prostate MRI images were recorded on a GE 750W or Philips Achieva 3.0 Tesla MRI scanner with high-resolution, small-field-of-view imaging consisting of axial T2, axial T1, coronal T2, sagittal T2, axial multiple b-value diffusion (multiple values up to 1200 or 1400), and dynamic contrast-enhanced 3D axial T1 with fat suppression sequence...
February 21, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28197393/preclinical-efficacy-and-safety-of-the-ty21a-vaccine-strain-for-intravesical-immunotherapy-of-non-muscle-invasive-bladder-cancer
#14
Sonia Domingos-Pereira, Valérie Cesson, Mathieu F Chevalier, Laurent Derré, Patrice Jichlinski, Denise Nardelli-Haefliger
Intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy can reduce recurrence/progression of non-muscle-invasive bladder cancer (NMIBC), although significant adverse events and treatment failure argue for alternative options. Here, we examined whether another attenuated live vaccine, Vivotif/Ty21a, used since more than 30 y against typhoid fever, may be safely used intravesically to improve bladder-tumor treatment. Mice-bearing MB49 orthotopic bladder-tumors treated with intravesical Ty21a or BCG were compared for survival and bacteria recovery...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28185020/natural-course-of-asymptomatic-abnormal-prostate-findings-incidentally-detected-by-ct-after-intravesical-bcg-therapy
#15
Masashi Matsushima, Eiji Kikuchi, Hirotaka Akita, Akira Miyajima, Mototsugu Oya, Masahiro Jinzaki
BACKGROUND: Detailed information is not currently available on the incidence, natural course, and management of asymptomatic abnormal prostate findings incidentally detected by radiologic evaluations after BCG therapy for non-muscle-invasive bladder cancer patients. METHODS: We identified 38 patients who were evaluated by contrast-enhanced CT scans before TUR-BT and after BCG therapy between 2006 and 2012. We evaluated the clinical courses of patients with abnormal radiologic findings of the prostate gland after BCG therapy...
February 10, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28168135/outcomes-of-bcg-induction-in-high-risk-non-muscle-invasive-bladder-cancer-patients-nmibc-a-retrospective-cohort-study
#16
Muhammad T Pirzada, Rashid Ghauri, Monis J Ahmed, Muhammad F Shah, Irfan Ul Islam Nasir, Jasim Siddiqui, Irfan Ahmed, Khurram Mir
Non-muscle-invasive bladder cancer (NMIBC) is categorized into high-risk and low-risk groups. Although, bacillus Calmette-Guerin (BCG) is the recommended adjuvant therapy of high-risk bladder tumor, optimal schedule (induction versus maintenance) of this therapy is a subject of debate. The objective was to evaluate outcomes of induction BCG in high-risk NMIBC patients at Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan and retrospective cohort study conducted in the department of urology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan...
January 5, 2017: Curēus
https://www.readbyqxmd.com/read/28165132/nonmuscle-invasive-bladder-cancer-what-s-changing-and-what-has-changed
#17
Ramanitharan Manikandan, Oscar Rodriguez, Rubén Parada, Joan Palou Redorta
PURPOSE: Nonmuscle-invasive bladder cancer (NMIBC) is a challenging disease to manage primarily due to its varied clinical course. The management of NMIBC has witnessed a widespread change with respect to its diagnosis and treatment. Although transurethral resection (TUR) and adjuvant bacillus Calmette-Guerin (BCG) stills remain the cornerstone, newer protocols has come into vogue to achieve optimal care. On the basis of a literature review, we aimed to establish 'what changes has already occurred and what is expected in the future' in NMIBC...
February 3, 2017: Urologia
https://www.readbyqxmd.com/read/28163086/long-term-survival-outcomes-with-intravesical-nanoparticle-albumin-bound-paclitaxel-for-recurrent-non-muscle-invasive-bladder-cancer-after-previous-bacillus-calmette-gu%C3%A3-rin-therapy
#18
Dennis J Robins, Wilson Sui, Justin T Matulay, Rashed Ghandour, Christopher B Anderson, G Joel DeCastro, James M McKiernan
OBJECTIVE: To report long-term follow-up results of a phase II trial of salvage intravesical nanoparticle albumin-bound (nab)-paclitaxel for patients with recurrent non-muscle-invasive bladder cancer after previous intravesical bacillus Calmette-Guérin (BCG) therapy. METHODS: This was a phase II trial investigating the use of intravesical nab-paclitaxel in patients with recurrent Tis, Ta, and T1 urothelial carcinoma who failed at least 1 prior induction course of intravesical BCG...
February 2, 2017: Urology
https://www.readbyqxmd.com/read/28149937/efficacy-of-mycobacterium-phlei-cell-wall-nucleic-acid-complex-mcna-in%C3%A2-bcg-unresponsive-patients
#19
Roger Li, John Amrhein, Zvi Cohen, Monique Champagne, Ashish M Kamat
Background: We have previously reported the results of a prospective multi-institutional study on the efficacy of MCNA in patients who recurred after intravesical BCG treatment [1]. Since that publication, a new standardized definition for BCG-unresponsiveness has been established [2]. Objective: We re-analyzed the oncologic outcomes following intravesical MCNA in patients classified as BCG-unresponsive according to the new definition. Methods: For this analysis, we focused on the enrolled patients who satisfied the requirements for BCG Unresponsiveness: i...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28126017/ruptured-aortic-aneurysm-due-to-mycobacterium-bovis-bcg-with-a-delayed-bacteriological-diagnosis-due-to-false-negative-result-of-the-mpb-64-immunochromatographic-assay
#20
J Simar, L Belkhir, B Tombal, E André
BACKGROUND: Adjuvant therapy with bacillus Calmette-Guerin (BCG), a live attenuated strain of Mycobacterium bovis, has become the treatment of choice for low-risk superficial bladder carcinoma following transurethral resection of the bladder. Complications following vesical BCG instillations are uncommon but, in some cases, severe side-effects can occur such as sepsis or mycotic aneurysm. Besides usual laboratory techniques used for the diagnosis of Mycobacterium tuberculosis complex (MTBC) infections (smear microscopy and cultures), commercial immunochromatographic assays detecting MBP64, a 24 kDa M...
January 26, 2017: BMC Research Notes
keyword
keyword
7101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"